Comparative Pharmacology
Head-to-head clinical analysis: GRIS PEG versus SELENIUM SULFIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIS PEG versus SELENIUM SULFIDE.
GRIS-PEG vs SELENIUM SULFIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by interfering with the polymerization of tubulin, thereby inhibiting fungal cell mitosis and nucleic acid synthesis.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
For tinea capitis and other dermatophyte infections: 500 mg oral daily as a single dose or in divided doses. For more severe infections, up to 1 g daily in divided doses.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
None Documented
None Documented
Terminal elimination half-life 14-24 hours. With continuous therapy, time to steady-state is ~3-5 days.
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Primarily renal (as glucuronide conjugates): ~80%; fecal/biliary: ~10-15%; unchanged drug <1%.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Category C
Category A/B
Antifungal
Antifungal / Antiseborrheic